On February 27, 2024 Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, reported its participation in the Leerink Partners Global Biopharma Conference 2024, taking place March 11-13 in Miami, Florida (Press release, Adagene, FEB 27, 2024, View Source [SID1234640503]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Adagene’s Chairman, Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will provide an update on its masked, anti-CTLA-4 SAFEbody ADG126, including key milestones for 2024. Company management will also host investor meetings.

Leerink Partners Global Biopharma Conference 2024

Date:
Tuesday, March 12
Presentation Time:
1:40 PM (Eastern Time)
Location:
The Fontainebleau Miami
A live webcast of the presentation will also be accessible in the Investors section of the company’s website at View Source A webcast replay will be available for at least 30 days.